目的 探究痹祺膠囊聯(lián)合依托考昔片治療膝骨性關(guān)節(jié)炎的臨床療效。方法 選取2015年2月—2017年10月天津市公安醫(yī)院收治的膝骨性關(guān)節(jié)炎患者140例為研究對(duì)象，按隨機(jī)數(shù)字表法將所有患者分為對(duì)照組和治療組，每組各70例。對(duì)照組口服依托考昔片，1片/次，1次/d；治療組在對(duì)照組基礎(chǔ)上口服痹祺膠囊，4粒/次，3次/d。兩組患者均治療4周。觀察兩組的臨床療效，比較兩組的視覺模擬評(píng)分法（VAS）評(píng)分、骨關(guān)節(jié)炎指數(shù)可視化量表（WOMAC）評(píng)分和健康調(diào)查簡表（SF-36）評(píng)分，以及核因子κB（NF-κB）、白細(xì)胞介素-1β（IL-1β）、腫瘤壞死因子-α（TNF-α）、基質(zhì)金屬蛋白酶-3（MMP-3）、Ⅰ型膠原交聯(lián)C-末端肽（CTX-Ⅰ）、Ⅱ型膠原C-末端肽（CTX-Ⅱ）、軟骨寡聚基質(zhì)蛋白（COMP）水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為81.43%、92.86%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組VAS評(píng)分、WOMAC評(píng)分均明顯降低，SF-36評(píng)分明顯升高，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些評(píng)分明顯優(yōu)于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清NF-κB、IL-1β、TNF-α水平均明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組血清CTX-Ⅰ、CTX-Ⅱ、COMP、MMP-3水平均明顯下降，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 痹祺膠囊聯(lián)合依托考昔片治療膝骨性關(guān)節(jié)炎具有較好的臨床療效，能改善臨床癥狀，緩解炎癥反應(yīng)，提高關(guān)節(jié)活動(dòng)功能，改善生活質(zhì)量，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Biqi Capsules combined with Etoricoxib Tablets in treatment of knee osteoarthritis. Methods Patients (140 cases) with knee osteoarthritis in Tianjin Public Security Hospital from February 2015 to October 2017 were randomly divided into control and treatment groups, and each group had 70 cases. Patients in the control group were po administered with Etoricoxib Tablets, 1 tablet/time, once daily. Patients in the treatment group were po administered with Biqi Capsules on the basis of the control group, 4 grains/time, three times daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and VAS scores, WOMAC scores, SF-36 scores, and the levels of serum NF-κB, IL-1β, TNF-α, CTX-Ⅰ, CTX-Ⅱ, COMP, and MMP-3 in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.43% and 92.86%, respectively, and there was difference between two groups (P < 0.05). After treatment, VAS scores and WOMAC scores in two groups were significantly decreased, but SF-36 scores in two groups were significantly increased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of serum NF-κB, IL-1β and TNF-α in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). After treatment, the levels of serum CTX-Ⅰ, CTX-Ⅱ, COMP, and MMP-3 in two groups were significantly decreased, and the difference was statistically significant in the same group (P < 0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P < 0.05). Conclusion Biqi Capsules combined with Etoricoxib Tablets has clinical curative effect in treatment of knee osteoarthritis, can improve clinical symptoms, alleviate inflammatory reaction, improve joint activity function, and improve quality of life, which has a certain clinical application value.